MI-389

Overview

MI-389 is a potent menin-MLL interaction inhibitor ( IC 50 =25 nM). MI-389 upregulates myeloid differentiation-related genes that are lowly expressed in primitive hematopoietic progenitor cells, thereby inducing myeloid differentiation phenotypic changes in MLL-rearranged leukemia cells. MI-389 competitively blocks the MG-H1-RAGE interaction to interfere with the AGEs-RAGE pathway, thus alleviating AGEs-induced HUVEC injury . MI-389 can be used in studies related to MLL-rearranged acute leukemia. (Pink: Ligands for Target Protein for PROTAC ligand ( HY-76719 ); Blue: Cereblon ligand ( HY-10984 ); Black: linker).

Application

Products | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-136688
• CAS No.: 2222635-92-7
• Molecular Formula: C35H35FN6O6
• Molecular Weight: 654.69
• Purity: 99.34%
• Storage: 4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Availability: In-stock

Source

Original product source